Welcome to BioSeeker Group!

Triple Analysis: Apoptosis, Angiogenesis and Cancer Vaccines

Additional Information

Published Date Mar 19, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 4328
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Apoptosis, Angiogenesis and Cancer Vaccines in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies by mechanism/target/effect of Apoptosis, Angiogenesis and Cancer Vaccines.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Apoptosis, Angiogenesis and Cancer Vaccines.

    To find out more about Triple Analysis: Apoptosis, Angiogenesis and Cancer Vaccines, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Apoptosis, Angiogenesis and Cancer Vaccines is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies by mechanism/target/effect of Apoptosis, Angiogenesis and Cancer Vaccines. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Apoptosis
The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 157 drug target strategies, and assesses them in 69 cancer indications.
This part is based on the following publication:
Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part II: Angiogenesis
The angiogenesis affecting cancer drug report part comprises defined and up to date development strategies for 252 drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part III: Cancer Vaccines
The cancer vaccine drug report part comprises defined and up to date development strategies for 196 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 137 identified drug targets, organized into 114 drug target strategies, and assesses them in 52 cancer indications.
This part is based on the following publication:
Cancer Vaccines: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Apoptosis
5.1 The Scope of this Report 33
6 Consider the Therapeutic Target Among Apoptotic Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 37-416
7 Emerging New Products to Established Ones: Drug Target Strategies of Apoptotic Drugs in Oncology by their Highest Stage of Development (157 Drug Target Strategies and 234 Drugs) 417-622
8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Cancer Drugs by Compound Strategy(7 Compound Strategies) 623-660
9 Selecting Indication for Apoptotic Drugs in Oncology (69 Cancer Indications) 661-776
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Apoptotic Drug Pipeline in Oncology by Investigator (158 Investigators and 234 Drugs) 777-1601
Disclaimer 1602
11 Drug Index 1603
12 Company Index 1611
Figures: Includes 7 Figures
Tables: Includes 315 Tables
Total Number of Pages: 1,617

Part II: Angiogenesis
5.1 The Scope of this Report 37
6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (177 Drug Targets) 41-421
7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development (170 Drug Target Strategies and 252 Drugs) 424-666
8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy (7 Compound Strategies) 667-709
9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology (70 Cancer Indications) 710-848
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (151 Investigators and 252 Drugs) 849-1685
12 Drug Index 1687
13 Company Index 1697
Figures: Includes 7 Figures
Tables: Includes 310 Tables
Total Number of Pages: 1,704

Part III: Cancer Vaccines
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (137 Drug Targets) 32-245
7 First-in-Class and Me-too Analysis of Cancer Vaccine Drugs (114 Drug Target Strategies and 196 Drugs) 246-262
8 Is First-in-Class the Best-in-Class? 263-386
9 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 387-413
10 The Competition Through Close Mechanistic Approximation of Cancer Vaccine Drugs 414-416
11 Selecting Indications for Cancer Vaccine Drugs (52 Cancer Indications) 417-492
12 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Company (114 Companies and 196 Drugs) 493-993
13 Disclaimer 994
Figures: Includes 5 Figures
Tables: Includes 239 Tables
Total Number of Pages: 1,007

This Report Includes the Following Companies:
Abbott
AC Immune
Acceleron Pharma
Access
Active Biotech
Adaptimmune
Adherex
Advanced Life Sciences
Advantagene
Advaxis
Advenchen
AEgera
AEterna Zentaris
Agennix
Agenus
Aida Pharmaceuticals
Aileron Therapeutics
Alnylam
AlphaVax
Ambit Biosciences
Ambrilia Biopharma
Amgen
Amphora
Anadys Pharmaceuticals
Anaphore
Anavex Life Sciences
Angiogen
Angiogenex
Angstrom Pharmaceuticals
Ansaris
Antisoma
Anza Therapeutics
Aphios
Apogenix
ApopLogic Pharmaceuticals
Arana Therapeutics
Argos Therapeutics
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
Austrianova
Avila Therapeutics
Basilea Pharmaceutica
Bavarian Nordic
Bayer
Bellicum Pharmaceuticals
BioAlliance Pharma
BioAxone
Biocad
Biogen Idec
BioInvent
BioLineRx
Biomas
Bionovo
BioNTech
BioSante
Biostar
BioVex
Boehringer Ingelheim
Bolder BioTechnology
BreakThrough Therapeutics
Bristol-Myers Squibb
BTG
Cancer Advances
Cancer Research Technology
CDG Therapeutics
Celecure
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Cellmid
Center of Molecular Immunology
Cephalon
CG Therapeutics
ChemoCentryx
Chemokine Therapeutics
China Sky One Medical
Chlorogen
Choongwae
Chroma Therapeutics
Circadian Technologies
Cleveland BioLabs
CombinatoRx
Coronado Biosciences
Cosmo Pharmaceuticals
CreaGene
Critical Outcome Technologies
CSL
Cue Biotech
CureVac
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytochroma
CytRx
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Deciphera Pharmaceuticals
Dendreon
DeveloGen
Dyax
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
EntreMed
Epeius Biotechnologies
EpiCept
Erimos
Etubics
Exelixis
ExonHit Therapeutics
Five Prime Therapeutics
Galena Biopharma
GammaCan
Generex
Genmab
GenOdyssee Pharmaceuticals
Genta
Genticel
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
Gliknik
GlobeImmune
GlycoGenesys
Glycotope
GPC Biotech
Gradalis
Green Cross
Harbor BioSciences
Heat Biologics
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Ichor Medical Systems
Idera Pharmaceuticals
ImClone Systems
immatics biotechnologies
ImmunoCellular Therapeutics
ImmunoFrontier
ImmunoGen
Immunotope
Immunovaccine
ImmuPharma
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Inovio
Insmed
Insys Therapeutics
Intracel
Intradigm
Introgen Therapeutics
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Jennerex Biotherapeutics
Johnson & Johnson
KAEL-GemVax
KAI Pharmaceuticals
Kalypsys
Karus Therapeutics
Keryx Biopharmaceuticals
Kirin Pharma
Kringle Pharma
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
Ligand
Lipotek
Lorus Therapeutics
Mannkind
MAT Biopharma
MediGene
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
Mersana Therapeutics
MethylGene
Micromet
MolMed
Mologen
Momotaro-Gene
Morvus Technology
Nemod Biotherapeutics
Neovacs
Nereus Pharmaceuticals
Nerviano Medical Sciences
NewSouth Innovations
NIH
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novacea
NovaLead
Novartis
NovaRx
Novelix
Novogen
Noxxon
Oasmia
OncoMune
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Onyvax
Orchestra Therapeutics
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
PanaGin
Patrys
Pepscan Therapeutics
Peptagen
PepTx
Peregrine Pharmaceuticals
Pfizer
Pharmacopeia
Pharmacyclics
PharmaForm
PharmaMar
Pharmexa
Pharminox
Philogen
PhiloGene
Pierre Fabre
Progen
Progenics Pharmaceuticals
ProMetic Life Sciences
Protein Sciences
Protgen
Protherics
PTC Therapeutics
QLT
Radient Pharmaceuticals
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
responsif
Rexahn
Rigel
Rosetta Genomics
Sanofi
Santaris Pharma
Sarepta Therapeutics
SBI Biotech
Scancell
SciClone Pharmaceuticals
Seattle Genetics
Semafore Pharmaceuticals
Senesco Technologies
Shionogi
Sigma-Tau
Simcere Pharmaceuticals
Spear Therapeutics
SRI International
Stainwei Biotech
SuperGen
Switch Pharma
SymBio Pharmaceuticals
Symbiotec
SynDevRx
Taiho
Takeda
TapImmune
Tau Therapeutics
Taxolog
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Therion Biologics
ThromboGenics
Tigris Pharmaceuticals
ToolGen
TopoTarget
Tracon Pharmaceuticals
Transgene
UCB
UMN Pharma
United Biomedical
Vaccinex
ValiRx
Vaxil BioTherapeutics
Vaximm
Vaxon Biotech
VBL Therapeutics
Vectura
Velacor Therapeutics
Vertex Pharmaceuticals
Vical
Wilex
VioQuest
Viragen
Viralytics
Virionics
ViroMed
ViroTarg
VM Discovery
Xerion
Zensun
Zydus Cadila
A Shortlist of Drugs Included are:
131I-tositumomab
A6
abagovomab
ABT-510
ADXS11-001
AE-37
AEG-35156
aflibercept
AGS-003
alvocidib
AME-133
AMG-386
Angiozyme
ANZ-207
apatinib
APG-101
ARQ-197
AS-101
AS-1411
astuprotimut-r
atrasentan
Auto TAG vaccine
AVX-701
axitinib
bardoxolone methyl
belagenpumatucel-L
belinostat
bevacizumab
BIBF-1120
BMS-690514
bortezomib
bosutinib
BP-GMAX-CD1
brivanib alaninate
BV-NSCLC-001
BZL-101
canfosfamide hydrochloride
CB-10-01
CDX-1307
cediranib
cenersen
CG-201
cilengitide
cintredekin besudotox
conatumumab
CreaVax-PC
crolibulin
CV-9103
CV-9201
CVac
DCVax-prostate
DI-17E6
dinaciclib
dovitinib lactate
dulanermin
E-75
E-7820
emepepimut-S
endostatin
ENMD-2076
enzastaurin hydrochloride
everolimus
Exherin
foretinib
fosbretabulin tromethamine
gataparsen
GI-4000
GliaAtak
GSK-2130579A
GT-111
GV-1001
GVAX
GVX-3322
HBP-347
HE-3235
Her-2/Neu peptides
Hi-8 MEL
HS-110
ibritumomab tiuxetan
icrucumab
ICT-107
idronoxil
imatinib mesilate
imetelstat
imMucin
IMO-2055
interleukin-12
intetumumab
IPP-204106
ISA-P53-01
JI-101
JX-594
kahalalide F
lenvatinib
lestaurtinib
linifanib
litronesib
lonaprisan
lumiliximab
LY-2275796
mapatumumab
MDX-1379
MGCD-265
MGN-1601
midostaurin
MKC-1
mocetinostat
motesanib diphosphate
motexafin gadolinium
muparfostat (IV)
MVA-BN Her-2 vaccine
navitoclax
NGR-TNF
noscapine
obinutuzumab
oblimersen sodium
ON-01910
Oncohist
OncoVAX
Onyvax-105
OTS-102
p.DOM-WT1-37/p.DOM-WT1-126 DNA
paclitaxel
PancAtak
panobinostat
PAT-SC1
pazopanib hydrochloride
PBI-1402
PCI-24781
PCI-27483
pegdinetanib
PF-4856884
plitidepsin
poly-ICLC
polyclonal antibody stimulator
ponatinib
ProstAtak
PROSTVAC
PSMA ADC
PTC-299
PX-12
quarfloxacin
quinacrine
R-(-)-gossypol
RAF-265
ramucirumab
regorafenib
retaspimycin
Reximmune-C
ridaforolimus
rindopepimut
rintatolimod
S-488410
sagopilone
SCIB-1
seliciclib
sipuleucel-T
sirolimus
sorafenib tosylate
SPC-2996
ß-lapachone
SU-6668
sunitinib malate
Survivac
talactoferrin alfa
TAS-102
tasquinimod
TB-403
telatinib
Tenarad
terameprocol
TG-4010
thymalfasin
tigapotide triflutate
tigatuzumab
tipapkinogene sovacivec
tipifarnib
tivozanib
TL-32711
TRC-105
triciribine phosphate
TroVax
TRU-016
vandetanib
velimogene aliplasmid
verpasep caltespen
vismodegib
vitespen
volasertib
volociximab
vosaroxin
VX-001
XL-147
XL-184
XL-647

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Apoptosis, Angiogenesis and Cancer Vaccines.
    To find out more about Triple Analysis: Apoptosis, Angiogenesis and Cancer Vaccines, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Apoptosis, Angiogenesis and Cancer Vaccines is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Colorectal Cancer, Prostate Cancer and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Prostate Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More


Triple Analysis: Breast Cancer, Cancer Vaccines and Peptides
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Breast Cancer), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Peptides). Learn More

Other selected research from the 'Oncology' category:


Leptin Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 410 companies plus partners who are today developing 537 Leptin pathway targeting drugs in 1840 developmental projects in cancer across 213 different targets. In addition, there are 3 suspended drugs and another 229 drugs where development has been ceased. Learn More


Nucleic Acid Therapies in Oncology: Drug Pathway Analyzer
There are today at least 373 nucleic acid drugs known to affect more than 228 specific intracellular signaling pathways for the treatment of more than 91 different tumor types. The rational for this plethora of treatment strategies is based on our increasing understanding of the 220 drug targets that are included in this drug-pathway analyzing tool. No less than 189 of these have been recorded with mutations and 36 drug targets have mutations which have been causally implicated in cancer. Learn More